Androgens are known drivers of prostate cancer, and inhibition of the androgen receptor (AR) signaling axis remains a mainstay of systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). The gene discussed is AR; the disease is prostate carcinoma.